|
|
||||||||
1 Depts of Pulmonary Diseases, 3 Physics and Medical Technology, and, 4 Clinical Epidemiology and Biostatistics, Institute for Cardiovascular Research ICaR-VU, VU University Medical Centre Amsterdam, The Netherlands, and 2 Dept of Cardiology, University Hospitals Leicester, NHS Trust, Leicester, UK.
CORRESPONDENCE: A. Vonk-Noordegraaf, Dept of Pulmonary diseases, VU University Medical Centre, De Boelelaan 1117, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands. Fax: 31 204444328. E-mail: a.vonk{at}vumc.nl
Keywords: Magnetic resonance imaging, N-terminal pro brain natriuretic peptide, pulmonary hypertension, right ventricle
Received: February 2, 2006
Accepted August 14, 2006
The aim of the current study was to investigate whether alterations in N-terminal pro brain natriuretic peptide (NT-proBNP) reflect changes in right ventricular structure and function in pulmonary hypertension patients during treatment.
The study consisted of 30 pulmonary hypertension patients; 15 newly diagnosed and 15 on long-term treatment. NT-proBNP, right heart catheterisation and cardiac magnetic resonance imaging measurements were performed, at baseline and follow-up.
There were no significant differences between newly diagnosed patients and those on treatment at baseline or follow-up with respect to NT-proBNP, haemodynamics and right ventricular parameters. Relative changes in NT-proBNP during treatment were correlated to the relative changes in right ventricular end-diastolic volume index (r = 0.59), right ventricular mass index (r = 0.62) and right ventricular ejection fraction (r = 0.81).
N-terminal pro brain natriuretic peptide measurements reflect changes in magnetic resonance imaging-measured right ventricular structure and function in pulmonary hypertension patients. An increase in N-terminal pro brain natriuretic peptide over time reflects right ventricular dilatation concomitant to hypertrophy and deterioration of systolic function.
This article has been cited by other articles:
![]() |
J. Suntharalingam, C. M. Treacy, N. J. Doughty, K. Goldsmith, E. Soon, M. R. Toshner, K. K. Sheares, R. Hughes, N. W. Morrell, and J. Pepke-Zaba Long-term Use of Sildenafil in Inoperable Chronic Thromboembolic Pulmonary Hypertension Chest, August 1, 2008; 134(2): 229 - 236. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Overbeek, G. P. van Nieuw Amerongen, A. Boonstra, E. F. Smit, and A. Vonk-Noordegraaf Possible role of imatinib in clinical pulmonary veno-occlusive disease Eur. Respir. J., July 1, 2008; 32(1): 232 - 235. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Behr and J. H. Ryu Pulmonary hypertension in interstitial lung disease Eur. Respir. J., June 1, 2008; 31(6): 1357 - 1367. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Fijalkowska and A. Torbicki Role of cardiac biomarkers in assessment of RV function and prognosis in chronic pulmonary hypertension Eur. Heart J. Suppl., December 1, 2007; 9(suppl_H): H41 - H47. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. van Wolferen, J. T. Marcus, A. Boonstra, K. M.J. Marques, J. G.F. Bronzwaer, M. D. Spreeuwenberg, P. E. Postmus, and A. Vonk-Noordegraaf Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension Eur. Heart J., May 2, 2007; 28(10): 1250 - 1257. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Vonk Noordegraaf and N. Westerhof Right ventricular ejection fraction and NT-proBNP are both indicators of wall stress in pulmonary hypertension Eur. Respir. J., April 1, 2007; 29(4): 622 - 623. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |